Filtered By:
Vaccination: Influenza Vaccine
This page shows you your search results in order of relevance. This is page number 20.
Order by Relevance | Date
Total 364 results found since Jan 2013.
Estimates of 2019-20 Seasonal Flu Vaccine Effectiveness Estimates of 2019-20 Seasonal Flu Vaccine Effectiveness
How effective has the seasonal influenza vaccine been during this most recent flu season? A new report provides interim estimates.Morbidity & Mortality Weekly Report
Source: Medscape Allergy Headlines - March 13, 2020 Category: Allergy & Immunology Tags: Public Health & Prevention Journal Article Source Type: news
Trump ’s State of Emergency Is an Admission of Failure by the U.S. Government
President Donald Trump’s declaration of a national emergency is designed to speed federal support to parts of America that are struggling to prepare for a coming surge of COVID-19 cases, unlocking $50 billion in aid, giving hospitals and doctors more freedom to handle a potential tsunami of sick patients and scrambling to make tests available. In a Rose Garden press conference Friday, Trump presented the emergency measures as proof that, “No nation is more prepared or more equipped to face down this crisis.”
But for epidemiologists, medical experts and current and former U.S. public health officials, the ...
Source: TIME: Health - March 13, 2020 Category: Consumer Health News Authors: W.J. Hennigan Tags: Uncategorized COVID-19 Source Type: news
First childhood flu helps explain why virus hits some people harder than others
Editor ’s note: This news release was updated March 3 to include a new link to the study about COVID-19 and to reflect that the study has been accepted by the journal eLife. The release was previously updated Feb. 5 to include new comments from Professor James Lloyd-Smith about screening practices use d by public health officials. Why are some people better able to fight off the flu than others? Part of the answer, according to a new study, is related to the first flu strain we encounter in childhood.Scientists from UCLA and the University of Arizona have found that people ’s ability to fight off the flu virus is d...
Source: UCLA Newsroom: Health Sciences - February 4, 2020 Category: Universities & Medical Training Source Type: news
President Trump Called Hydroxychloroquine a ‘Game Changer,’ But Experts Warn Against Self-Medicating With the Drug. Here’s What You Need to Know
After President Trump, late last week, expressed great confidence in the promise of a new COVID-19 therapy that combines two existing prescription medications, supplies of these two drugs rapidly began disappearing from pharmacy shelves. The U.S. Food and Drug Administration allowed an Indian company previously restricted from importing drug products into the US to now start manufacturing one of the drugs. And U.S. plants began gearing up to produce enough to meet the surge in demand.
But in those few days, a few people who began self medicating with the drugs in an effort to prevent COVID-19 have died, and others have bee...
Source: TIME: Health - March 24, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
How to Flatten the Curve on Coronavirus
One chart explains why slowing the spread of the infection is nearly as important as stopping it.
Source: NYT Health - March 27, 2020 Category: Consumer Health News Authors: Siobhan Roberts Tags: Coronavirus (2019-nCoV) Quarantines Epidemics Shortages Hospitals Vaccination and Immunization Influenza Hygiene and Cleanliness Centers for Disease Control and Prevention Economist, The National Institute of Allergy and Infectious Dis Source Type: news
Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19.
It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
All Your Coronavirus Questions, Answered
One of the worst symptoms of any plague is uncertainty—who it will strike, when it will end, why it began. Merely understanding a pandemic does not stop it, but an informed public can help curb its impact and slow its spread. It can also provide a certain ease of mind in a decidedly uneasy time. Here are some of the most frequently asked questions about the COVID-19 pandemic from TIME’s readers, along with the best and most current answers science can provide.
A note about our sourcing: While there are many, many studies underway investigating COVID-19 and SARS-CoV-19, the novel coronavirus that causes the illn...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: TIME Staff Tags: Uncategorized COVID-19 Explainer Source Type: news
“Host immune response-inspired development of the influenza vaccine”
Influenza is a respiratory illness caused by influenza viruses. It is a major public health concern with a huge economic impact worldwide [1 –3]. Vaccines against influenza virus are the best method of protection. The very young, the elderly, pregnant women and immune-compromised individuals are at enhanced risk for severe complications during infection. Therefore, these individuals form special target groups for influenza vaccination. Due to the rise in life expectancy, the elderly population is growing in countries with an aging population.
Source: Annals of Allergy, Asthma and Immunology - April 19, 2020 Category: Allergy & Immunology Authors: Angela Choi, Adolfo Garc ía-Sastre, Michael Schotsaert Tags: Review Source Type: research
Host immune response –inspired development of the influenza vaccine
To assess the current and future development of influenza vaccines.
Source: Annals of Allergy, Asthma and Immunology - April 19, 2020 Category: Allergy & Immunology Authors: Angela Choi, Adolfo Garc ía-Sastre, Michael Schotsaert Tags: Review Source Type: research
Moderna ’s COVID-19 Vaccine Shows Promise, Generating Positive Immune Responses in an Early Study
Earlier today, the biotech company Moderna reported positive results from a phase 1 study of its experimental COVID-19 vaccine, which was was among the first to begin testing in healthy human volunteers in mid-March.
The study, led by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health, involves 45 healthy people who received one of three different doses of the vaccine. According to Moderna, there are encouraging early signs that the shot generates antibodies against the COVID-19 virus, SARS-CoV-2, in levels that were similar to or higher than those seen in the plasma of p...
Source: TIME: Health - May 18, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Positive Outcome in a COVID-19 patient with Common Variable Immunodeficiency after IVIG
We present a case of an immunodeficient patient patient who has recovered from COVID-19 infection. This is a 53-year-old female with Common Variable Immunodeficiency diagnosed in 1996 and has been on regular IVIG replacement therapy, GAMUNEX ®-C 40 grams (520 mg/ kg/ dose) every 2 weeks. Last IgG trough level was 1478 mg/dl on 11-12-19. High dose influenza vaccine administered in September 2019. The patient has also hypothyroidism, bronchiectasis, and Sjogren’s Syndrome treated with hydroxychloroquine 400 mg daily.
Source: Annals of Allergy, Asthma and Immunology - June 3, 2020 Category: Allergy & Immunology Authors: Rana Aljaberi, Kholoud Wishah Tags: Letters Source Type: research
Host immune responses to influenza infection and vaccines
Before the ravaging appearance of the severe acute respiratory syndrome coronavirus 2, influenza viruses have been among the major players in the history of health disasters over the past century.1,2 Because the 1918 Spanish flu pandemic claimed more than 50 million lives followed by annual resurgence of varying degrees of morbidity and mortality, the influenza vaccine program has driven platform development and global collaborative surveillance networks. These networks support the definition of antigenic shifts that drive annual vaccine specificities for manufacturing responses.
Source: Annals of Allergy, Asthma and Immunology - June 19, 2020 Category: Allergy & Immunology Authors: Renata J.M. Engler, Michael R. Nelson Tags: Editorial Source Type: research
Flu Vaccine Only 39% Effective This Past Season, CDC Panel Says Flu Vaccine Only 39% Effective This Past Season, CDC Panel Says
The influenza vaccine was even less effective against A/H1N1pmd09 virus but was better against B/Victoria virus, according to a CDC panel. They also voted on a new meningococcal vaccine.Medscape Medical News
Source: Medscape Allergy Headlines - June 25, 2020 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news
Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin
We present a case of a patient with immunodeficiency who has recovered from coronavirus disease 2019 (COVID-19). The patient is a 53-year-old woman who received a diagnosis of common variable immunodeficiency in 1996 and has been on regular intravenous immunoglobulin (IVIG) replacement therapy with Gamunex-C 40 g (520 mg/kg/dose) every 2 weeks. The last immunoglobulin G trough level was 1478 mg/dL on November 12, 2019, and a high-dose influenza vaccine was administered in September 2019. The patient also has hypothyroidism, bronchiectasis, and Sjogren's syndrome treated with hydroxychloroquine 400 mg daily.
Source: Annals of Allergy, Asthma and Immunology - June 3, 2020 Category: Allergy & Immunology Authors: Rana Aljaberi, Kholoud Wishah Tags: Letters Source Type: research
Protein Nanoparticles for Antigen Display in Vaccines
The technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/e1, where other antigens can be inserted and the chimeric protein retains the ability to form capsid-like particles. The technology describes the insertion of one or more copies of influenza epitopes derived from the globular head or the stem region of hemagglutinin protein into or around the c/e1 loop of the core protein. The nanoparticles formed by the use of Hep...
Source: NIH OTT Licensing Opportunities - July 6, 2020 Category: Research Authors: ott-admin Source Type: research
